Company news: IMS, BMS and AstraZeneca

Share this article:
One month after divesting itself of a promotional and medical audit business from one-time rival SDI, analytics firm IMS Health is once again expanding its reach. The Danbury, CT, company announced Tuesday it is buying the data-mining company PharmARC, which is based in Bangalore, India.

Diabetes drug dapagliflozin is facing another setback. The FDA is asking for more risk information regarding the joint AstraZeneca/Bristol-Myers pharmaceutical that is intended to treat adult diabetes 2, reports Reuters and Marketwatch. This is the third time the FDA has delayed making a decision about the SGLT2 inhibitor. The FDA indicated in July 2011 that it was alarmed by breast and bladder cancer rates among patients. Analysts note the agency is particularly skittish in light of the finding that diabetes drug Avandia was linked to heart attacks. A research note by Bernstein analyst Tim Anderson adds that the field is facing a glut, rendering the drug unwanted by diabetes experts.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters